Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: Novartis, Abbott Earnings; Using mL Cuts Mis-Dosing; Labels Need Proprietary Blend, Capsule Ingredients

This article was originally published in The Tan Sheet

Executive Summary

Novartis consumer up 5%; adult products drive Abbott Nutrition growth; medication errors drop when mL is unit of measurement; ingredients of proprietary blends must be labeled; include capsule ingredients on labels; and Herbalife defends nutrition clubs.

You may also be interested in...



CHPA Adopts Dosing Guidelines For OTC Pediatric Liquids

The Consumer Healthcare Products Association recommends a standardized labeling format for OTC pediatric oral liquids to help prevent accidental overdoses and misdosing

FDA Gets Strict On Liquid OTC Dosing Devices In Draft Guidance

Some drug firms may need to alter their product packaging and labeling to comply with FDA's guidance on dosing device labeling for liquid OTCs

China VBP, Localization And Other Strategies - How Far And Which Way?

Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS107035

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel